Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 4/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241626 | 0.88 | PDGFRA (0.56) | PDGFRAKDRPDGFRBFGFR2 | |
| SCHEMBL12663519 | 0.88 | PDGFRA (0.51) | PDGFRAKDRPDGFRBFGFR2SRC | |
| SCHEMBL28535002 | 0.88 | PDGFRA (0.56) | PDGFRAKDRPDGFRBFGFR2 | |
| SCHEMBL12444104 | 0.84 | PDGFRA (0.76) | PDGFRAKDRPDGFRBFGFR2 | |
| SCHEMBL31241622 | 0.84 | PDGFRA (0.48) | PDGFRAKDRPDGFRBFGFR2SRC | |
| SCHEMBL28534056 | 0.84 | PDGFRA (0.48) | PDGFRAKDRPDGFRBFGFR2SRC | |
| SCHEMBL557790 | 0.82 | PDGFRA (0.61) | PDGFRAKDRPDGFRBFGFR2 | |
| SCHEMBL22435917 | 0.81 | KDR (0.57) | PDGFRAKDRPDGFRBFGFR2RIPK1 | |
| SCHEMBL15882967 | 0.81 | PDGFRA (0.54) | PDGFRAKDRPDGFRBFGFR2RIPK1 | |
| SCHEMBL12663452 | 0.81 | PDGFRA (0.48) | PDGFRAKDRPDGFRBFGFR2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217896-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217896-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | FGFR1, PDGFRA, KIF18B | PDGFRA 2/4885KDR 379/4885PDGFRB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.